GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abiomed Inc (NAS:ABMD) » Definitions » EBITDA

Abiomed (Abiomed) EBITDA : $282 Mil (TTM As of Sep. 2022)


View and export this data going back to 1987. Start your Free Trial

What is Abiomed EBITDA?

Abiomed's EBITDA for the three months ended in Sep. 2022 was $65 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 was $282 Mil.

During the past 12 months, the average EBITDA Growth Rate of Abiomed was -2.10% per year. During the past 3 years, the average EBITDA Growth Rate was 6.00% per year. During the past 5 years, the average EBITDA Growth Rate was 21.40% per year. During the past 10 years, the average EBITDA Growth Rate was 49.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Abiomed was 106.90% per year. The lowest was -156.40% per year. And the median was 6.00% per year.

Abiomed's EBITDA per Share for the three months ended in Sep. 2022 was $1.42. Its EBITDA per share for the trailing twelve months (TTM) ended in Sep. 2022 was $6.14.

During the past 12 months, the average EBITDA per Share Growth Rate of Abiomed was -2.60% per year. During the past 3 years, the average EBITDA per Share Growth Rate was 6.20% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 21.00% per year. During the past 10 years, the average EBITDA per Share Growth Rate was 47.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Abiomed was 102.20% per year. The lowest was -136.20% per year. And the median was 14.60% per year.


Abiomed EBITDA Historical Data

The historical data trend for Abiomed's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abiomed EBITDA Chart

Abiomed Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 168.14 238.93 269.65 253.65 284.80

Abiomed Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.40 71.99 72.29 72.67 64.72

Competitive Comparison of Abiomed's EBITDA

For the Medical Devices subindustry, Abiomed's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abiomed's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Abiomed's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Abiomed's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Abiomed's EBITDA for the fiscal year that ended in Mar. 2022 is calculated as

Abiomed's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Mar. 2022, Abiomed's EBITDA was $285 Mil.

Abiomed's EBITDA for the quarter that ended in Sep. 2022 is calculated as

Abiomed's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Sep. 2022, Abiomed's EBITDA was $65 Mil.

EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $282 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Abiomed  (NAS:ABMD) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Abiomed EBITDA Related Terms

Thank you for viewing the detailed overview of Abiomed's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Abiomed (Abiomed) Business Description

Traded in Other Exchanges
N/A
Address
22 Cherry Hill Drive, Danvers, MA, USA, 01923
Abiomed Inc provides temporary mechanical circulatory support devices that are primarily used by interventional cardiologists and heart surgeons. The firm's products are used for patients in need of hemodynamic support before, during, or after angioplasty and heart surgery procedures. Abiomed receives the majority of revenue from its Impella product portfolio, which includes percutaneous micro heart pumps with integration motors and sensors and percutaneous catheter-based axial flow pumps. Abiomed generates the majority of its revenue in the United States.
Executives
Matthew T. Plano officer: VP, GLOBAL OPERATIONS C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923
Martin P Sutter director 2170 BUCKTHORNE PLACE, SUITE 170, THE WOODLAND TX 77380
David M Weber officer: Chief Operating Officer 2341 ROMANO CIRCLE, PLEASANTON CA 94566
Todd A Trapp officer: Vice President, CFO C/O WATTS WATER TECHNOLOGIES, INC., 815 CHESTNUT STREET, NORTH ANDOVER MA 01845
Michael R Minogue director, officer: President & CEO 22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923
Paul Thomas director ONE MILLENNIUM WAY, BRANCHBURG NJ 08876
Paula A Johnson director 22 CHERRY HILL DRIVE, DANVERS MA 01923
Myron L Rolle director 1 NASHUA STREET, APARTMENT 1701, BOSTON MA 02114-1625
Dorothy E Puhy director DANA FARBER CANCER INSTITUTE, 44 BINNEY STREET, RM. D1632, BOSTON MA 02115
Andrew J Greenfield officer: VP Healthcare Solutions 14 HILLSIDE DRIVE, GEORGETOWN MA 01833
Marc A Began officer: VP & General Counsel C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923
Michael G Howley officer: Vice President 22 CHERRY HILL DRIVE, DANVERS MA 01923
William J Bolt officer: SVP, DA and QA C/O ABIOMED INC, 22 CHERRY HILL DRIVE, DANVERS MA 01923
Rose Eric A Md director 161 FORT WASHINGTON AVENUE, 7TH FLOOR, NEW YORK NY 10032
Henri A Termeer director ONE KENDALL SQUARE, CAMBRIDGE MA 02139